We don't know if Mylan's (MYL) going to get Perrigo (PRGO) or whether someone else wants Mylan -- mainly Teva Pharmaceutical (TEVA). I think Mylan should be up big because if it gets Perrigo, that would be fantastic.
Still, what it has done, once again, is put the spotlight on a whole segment of drug stocks that haven't been moving of late. For example, the four horsemen of the big pharma apocalypse are back -- Biogen (BIIB), Celgene (CELG), Gilead (GILD) and Regeneron (REGN). You are seeing Mallinckrodt (MNK) and Horizon (HZNP) -- a little like Teva and Mylan -- exploding higher. You have the second-tier biotechs, the Jazz Pharma (JAZZ) and Vertex (VRTX) taking off.
It's basically just another jump-ball moment for off-the-beaten-track drug stocks.
This Mylan deal -- buy or sell -- is going to be the talk for the next few days. I sense the moves aren't over.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
Despite fluff and puff of UNH's analysts' day, little here screams for getting in right now.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.
Email
Email sent
Thank you, your email to has been sent successfully.
